NFE2L2 and non-small cell lung carcinoma: ML385, in conjunction with carboplatin, has been shown to have a strong anticancer effect in preclinical models of NSCLC, demonstrating the potential of NRF2 as a therapeutic target for advanced NSCLC [11].